

CLASSIFICATION: THYROID HORMONE COMBINATION (T4 + T3)
ACTIVE SUBSTANCES:
- LEVOTHYROXINE SODIUM 50 MCG
- LIOTHYRONINE SODIUM 12.5 MCG
FORM: 100 TABLETS x 62.5 MCG
ACTIVE HALF-LIFE: T4 ~7 DAYS; T3 ~1 DAY
DOSAGE: MEN 12.5-25 MCG/DAY
ACNE: NOT TYPICAL
WATER RETENTION: NONE EXPECTED
HIGH BLOOD PRESSURE (HBP): POSSIBLE
HEPATOTOXICITY: NONE EXPECTED
AROMATIZATION: NONE
MANUFACTURER: ABDI IBRAHIM
Bitiron combines two bioidentical thyroid hormones in a single tablet: levothyroxine (T4) 50 mcg and liothyronine (T3) 12.5 mcg. The fixed 4:1 ratio supplies the prohormone (T4) and the active hormone (T3) together, which some clinicians consider when carefully individualizing therapy for hypothyroidism. As with all thyroid medications, this is a prescription product and must be used only under licensed medical supervision. Thyroid hormones carry boxed warnings that they should not be used for weight loss in euthyroid individuals.
Most patients achieve reliable symptom control with T4 alone because peripheral tissues convert T4 into T3 as needed. However, a subset of patients continue to report residual symptoms despite apparently adequate T4 dosing and normal labs. In these select cases, a clinician may trial combination therapy. The rationale is to provide a modest, steady amount of circulating T3 while maintaining a physiologic T4 background. Evidence across randomized trials is mixed; some patients prefer combination therapy, while others do equally well on T4 alone. Your endocrinologist will decide whether a T4/T3 combination fits your situation.
T4 (levothyroxine) is a long-acting prohormone with a half-life of about a week, offering day-to-day stability and serving as a reservoir that converts to T3 in tissues. T3 (liothyronine) is the active hormone with a shorter half-life (~1 day in euthyroid subjects) and a faster onset, which is why some patients feel clinical changes sooner when T3 is introduced. The fixed 4:1 ratio (T4:T3 by weight) in Bitiron mirrors the traditional "liotrix" concept used in combination products.
Form & strength: each tablet supplies 50 mcg T4 + 12.5 mcg T3 (total 62.5 mcg). Therapy is individualized based on age, cardiovascular status, comorbidities, and lab targets. Many clinicians prefer a low start (for example, 1/2–1 tablet daily) with adjustments every 2–3 weeks, watching symptoms, heart rate, blood pressure, and labs. In older adults or those with coronary disease/arrhythmia risk, extremely conservative initiation and slower titration are standard.
Split dosing? Because T3 has a shorter half-life than T4, some clinicians split the daily dose (morning + early afternoon) to smooth peaks. Your prescriber will advise if this is appropriate or if once-daily use is best for you.
For authoritative labeling on indications, boxed warnings, and pharmacology of the T3 and T4 components, see the FDA prescribing information for liothyronine and levothyroxine. An example reference is the FDA Cytomel (liothyronine) label.
Over-replacement manifests as hyperthyroid-like effects: palpitations, tachycardia, tremor, heat intolerance, anxiety, insomnia, diarrhea, weight loss, or menstrual changes. Long-term excessive dosing can reduce bone mineral density. Cardiovascular caution is crucial in older adults or those with known heart disease.
Drug & supplement interactions: iron, calcium, aluminum/magnesium antacids, bile-acid sequestrants, sucralfate, and some phosphate binders can impair absorption—dose separation (often 4 hours) is commonly advised. Enzyme inducers (e.g., certain anticonvulsants), estrogen therapy, and some GI conditions can alter requirements. Anticoagulants (e.g., warfarin) and antidiabetic agents may need dose reviews after thyroid dose changes. Always share your full med/supplement list with your clinician.
Thyroid therapy is one pillar of a broader health strategy that also includes nutrition, sleep, stress management, and appropriate training. Many athletes and physique-focused users aim to keep hormones, lipids, and blood pressure in check while they pursue performance goals. Bitiron is not a shortcut for fat loss; it exists to correct thyroid hormone deficiency under medical supervision.
This listing is for Abdi İbrahim Bitiron tablets (100 count, each 62.5 mcg total: T4 50 mcg + T3 12.5 mcg). Store at room temperature, away from moisture and light. Keep out of reach of children.
Medical disclaimer: Information for educational purposes only; not a substitute for professional medical advice. Use prescription thyroid therapy only as directed by a licensed clinician.
Bitiron supplies both levothyroxine (T4) and liothyronine (T3) in a fixed 4:1 ratio. Some patients feel better on combination therapy, while many do well on T4 alone. Your clinician decides based on symptoms and labs.
Therapy is individualized. Many clinicians start low (e.g., 1/2–1 tablet daily) and adjust every 2–3 weeks. Older adults or those with heart disease usually start with very conservative dosing.
Sometimes. Due to T3's shorter half-life, some clinicians split the dose (morning and early afternoon) to smooth peaks. Follow your prescriber's advice.
Yes—iron, calcium, antacids, bile-acid binders, and others can reduce absorption; separate dosing. Anticoagulants and antidiabetic drugs may need review after thyroid dose changes. Always inform your clinician.
No. Thyroid hormones have boxed warnings and must not be used for weight loss in euthyroid patients. Bitiron is prescription therapy for diagnosed thyroid conditions only.
Please log in to write Bitiron review.
CLASSIFICATION: THYROID HORMONE
ACTIVE SUBSTANCE: LIOTHYRONINE SODIUM
FORM: 100 TABLETS x 25 MCG
ACTIVE HALF-LIFE: 1 DAY
DOSAGE: MEN 25-75 MCG/DAY
ACNE: NO
WATER RETENTION: NO
HIGH BLOOD PRESSURE (HBP): YES
HEPATOTOXICITY: NO
AROMATIZATION: NO
MANUFACTURER: KALPA PHARMACEUTICALS
CLASSIFICATION: BETA-2 AGONIST, BRONCHODILATOR
ACTIVE SUBSTANCE: CLENBUTEROL HYDROCHLORIDE
FORM: 100 TABLETS x 40 MCG
ACTIVE HALF-LIFE: 48-72 HOURS
DOSAGE: MEN 40-160 MCG/DAY
ACNE: NO
WATER RETENTION: NO
HIGH BLOOD PRESSURE (HBP): NO
HEPATOTOXICITY: NO
AROMATIZATION: NO
MANUFACTURER: KALPA PHARMACEUTICALS
LABORATORY TESTED: VIEW LAB RESULTS
CLASSIFICATION: BETA-2 AGONIST, BRONCHODILATOR
ACTIVE SUBSTANCE: CLENBUTEROL HYDROCHLORIDE
FORM: 100 PILLS x 40 MCG
ACTIVE HALF-LIFE: 48-72 HOURS
DOSAGE: MEN 40-160 MCG/DAY
ACNE: NO
WATER RETENTION: NO
HIGH BLOOD PRESSURE (HBP): NO
HEPATOTOXICITY: NO
AROMATIZATION: NO
MANUFACTURER: DRAGON PHARMA
LABORATORY TESTED: VIEW LAB RESULTS
CLASS: BETA-2 AGONIST, BRONCHODILATOR
ACTIVE SUBSTANCES:
- 30 MCG CLENBUTEROL HYDROCHLORIDE
- 5.6 MG YOHIMBINE HYDROCHLORIDE
MIXED FORM: 10 ML VIAL x 5.8 MG
ACTIVE HALF-LIFE: 48-72 HOURS
DOSAGE: MEN 3.4-12.16 MG/DAY
ACNE: NO
WATER RETENTION: NO
HIGH BLOOD PRESSURE (HBP): NO
HEPATOTOXICITY: NO
AROMATIZATION: NO
MANUFACTURER: DRAGON PHARMA
LABORATORY TESTED: VIEW LAB RESULTS
CLASSIFICATION: Β2-ADRENERGIC AGONIST
ACTIVE SUBSTANCE: SALBUTAMOL
FORM: 100 PILLS x 10 MG
ACTIVE HALF-LIFE: 6 HOURS
DOSAGE: MEN 100-200 MCG/DAY
ACNE: NO
WATER RETENTION: NO
HIGH BLOOD PRESSURE (HBP): NO
HEPATOTOXICITY: VERY LOW
AROMATIZATION: NO
MANUFACTURER: DRAGON PHARMA
CLASSIFICATION: THYROID HORMONE
ACTIVE SUBSTANCE: LIOTHYRONINE SODIUM
FORM: 100 PILLS x 25 MCG
ACTIVE HALF-LIFE: 1 DAY
DOSAGE: MEN 25-75 MCG/DAY
ACNE: NO
WATER RETENTION: NO
HIGH BLOOD PRESSURE (HBP): YES
HEPATOTOXICITY: NO
AROMATIZATION: NO
MANUFACTURER: DRAGON PHARMA
CLASS: BETA-2 AGONIST, THYROID HORMONE
ACTIVE SUBSTANCES:
- 37 MCG CLENBUTEROL HYDROCHLORIDE
- 25 MCG LIOTHYRONINE SODIUM
- 5.4 MG YOHIMBINE HYDROCHLORIDE
MIXED FORM: 100 PILLS x 6.02 MG
ACTIVE HALF-LIFE: 48-72 HOURS
DOSAGE: MEN 3.4-12.16 MG/DAY
ACNE: NO
WATER RETENTION: NO
HIGH BLOOD PRESSURE (HBP): NO
HEPATOTOXICITY: NO
AROMATIZATION: NO
MANUFACTURER: DRAGON PHARMA
CLASSIFICATION: THYROID HORMONE (T4)
ACTIVE SUBSTANCE: LEVOTHYROXINE SODIUM
FORM: 50 TABLETS x 100 MCG
ACTIVE HALF-LIFE: ~7 DAYS
DOSAGE: MEN 12.5-25 MCG/DAY
ACNE: NOT TYPICAL
WATER RETENTION: NONE EXPECTED
HIGH BLOOD PRESSURE (HBP): NOT TYPICAL
HEPATOTOXICITY: NONE EXPECTED
AROMATIZATION: NONE
MANUFACTURER: ABDI IBRAHIM